Measuring quality of life in progressive supranuclear palsy: The PSP-QoL

Anette Schrag, Jeremy Hobart, Caroline Selai, Niall Quinn, Andrew J. Lees, Irene Litvan, Anthony Lang, James Howard Bower, David Burn

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

Introduction Progressive supranuclear palsy (PSP) is a neurodegenerative disorder causing parkinsonism, visual dysfunction, and balance impairment, as well as cognitive impairment and psychiatric complications. These problems, together with the emotional and social consequences of having a progressively disabling disease with shortened life expectancy, have an enormous impact on patients' health-related quality of life (HRQoL). PSP was first delineated as a distinct disorder, separate from Parkinson's disease, in 1962. It is sometimes referred to as Steele–Richardson–Olszewski syndrome after the scientists who originally described the condition. It is estimated that the disease has a prevalence of 6 per 100,000, similar to that of motor neuron disease, with the average age of onset being in the seventh decade. Mean survival from the onset of symptoms is approximately 6 years. To date, there has been little validation of any HR-QoL generic instruments in this patient group. In one small-scale study, some limited evidence for the appropriateness of the European Quality of Life Five Dimensions (EQ-5D) in this patient group was found, but less support was found for the 36-Item Short-Form Health Survey (SF-36), which some patients indicated did not cover areas of relevance to them. The Parkinson's Disease Questionnaire (PDQ-39) has been assessed for its suitability in this patient group, but it was found to lack some aspects of quality of life that are important to patients with PSP.

Original languageEnglish (US)
Title of host publicationQuality of Life Measurement in Neurodegenerative and Related Conditions
PublisherCambridge University Press
Pages52-59
Number of pages8
ISBN (Electronic)9780511975363
ISBN (Print)9780521829014
DOIs
StatePublished - Jan 1 2011

Fingerprint

Progressive Supranuclear Palsy
Quality of Life
Parkinson Disease
Motor Neuron Disease
Parkinsonian Disorders
Life Expectancy
Health Surveys
Age of Onset
Neurodegenerative Diseases
Psychiatry
Survival

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Schrag, A., Hobart, J., Selai, C., Quinn, N., Lees, A. J., Litvan, I., ... Burn, D. (2011). Measuring quality of life in progressive supranuclear palsy: The PSP-QoL. In Quality of Life Measurement in Neurodegenerative and Related Conditions (pp. 52-59). Cambridge University Press. https://doi.org/10.1017/CBO9780511975363.006

Measuring quality of life in progressive supranuclear palsy : The PSP-QoL. / Schrag, Anette; Hobart, Jeremy; Selai, Caroline; Quinn, Niall; Lees, Andrew J.; Litvan, Irene; Lang, Anthony; Bower, James Howard; Burn, David.

Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press, 2011. p. 52-59.

Research output: Chapter in Book/Report/Conference proceedingChapter

Schrag, A, Hobart, J, Selai, C, Quinn, N, Lees, AJ, Litvan, I, Lang, A, Bower, JH & Burn, D 2011, Measuring quality of life in progressive supranuclear palsy: The PSP-QoL. in Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press, pp. 52-59. https://doi.org/10.1017/CBO9780511975363.006
Schrag A, Hobart J, Selai C, Quinn N, Lees AJ, Litvan I et al. Measuring quality of life in progressive supranuclear palsy: The PSP-QoL. In Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press. 2011. p. 52-59 https://doi.org/10.1017/CBO9780511975363.006
Schrag, Anette ; Hobart, Jeremy ; Selai, Caroline ; Quinn, Niall ; Lees, Andrew J. ; Litvan, Irene ; Lang, Anthony ; Bower, James Howard ; Burn, David. / Measuring quality of life in progressive supranuclear palsy : The PSP-QoL. Quality of Life Measurement in Neurodegenerative and Related Conditions. Cambridge University Press, 2011. pp. 52-59
@inbook{eda0cabfe7294e989d3808e61e9e7cfb,
title = "Measuring quality of life in progressive supranuclear palsy: The PSP-QoL",
abstract = "Introduction Progressive supranuclear palsy (PSP) is a neurodegenerative disorder causing parkinsonism, visual dysfunction, and balance impairment, as well as cognitive impairment and psychiatric complications. These problems, together with the emotional and social consequences of having a progressively disabling disease with shortened life expectancy, have an enormous impact on patients' health-related quality of life (HRQoL). PSP was first delineated as a distinct disorder, separate from Parkinson's disease, in 1962. It is sometimes referred to as Steele–Richardson–Olszewski syndrome after the scientists who originally described the condition. It is estimated that the disease has a prevalence of 6 per 100,000, similar to that of motor neuron disease, with the average age of onset being in the seventh decade. Mean survival from the onset of symptoms is approximately 6 years. To date, there has been little validation of any HR-QoL generic instruments in this patient group. In one small-scale study, some limited evidence for the appropriateness of the European Quality of Life Five Dimensions (EQ-5D) in this patient group was found, but less support was found for the 36-Item Short-Form Health Survey (SF-36), which some patients indicated did not cover areas of relevance to them. The Parkinson's Disease Questionnaire (PDQ-39) has been assessed for its suitability in this patient group, but it was found to lack some aspects of quality of life that are important to patients with PSP.",
author = "Anette Schrag and Jeremy Hobart and Caroline Selai and Niall Quinn and Lees, {Andrew J.} and Irene Litvan and Anthony Lang and Bower, {James Howard} and David Burn",
year = "2011",
month = "1",
day = "1",
doi = "10.1017/CBO9780511975363.006",
language = "English (US)",
isbn = "9780521829014",
pages = "52--59",
booktitle = "Quality of Life Measurement in Neurodegenerative and Related Conditions",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Measuring quality of life in progressive supranuclear palsy

T2 - The PSP-QoL

AU - Schrag, Anette

AU - Hobart, Jeremy

AU - Selai, Caroline

AU - Quinn, Niall

AU - Lees, Andrew J.

AU - Litvan, Irene

AU - Lang, Anthony

AU - Bower, James Howard

AU - Burn, David

PY - 2011/1/1

Y1 - 2011/1/1

N2 - Introduction Progressive supranuclear palsy (PSP) is a neurodegenerative disorder causing parkinsonism, visual dysfunction, and balance impairment, as well as cognitive impairment and psychiatric complications. These problems, together with the emotional and social consequences of having a progressively disabling disease with shortened life expectancy, have an enormous impact on patients' health-related quality of life (HRQoL). PSP was first delineated as a distinct disorder, separate from Parkinson's disease, in 1962. It is sometimes referred to as Steele–Richardson–Olszewski syndrome after the scientists who originally described the condition. It is estimated that the disease has a prevalence of 6 per 100,000, similar to that of motor neuron disease, with the average age of onset being in the seventh decade. Mean survival from the onset of symptoms is approximately 6 years. To date, there has been little validation of any HR-QoL generic instruments in this patient group. In one small-scale study, some limited evidence for the appropriateness of the European Quality of Life Five Dimensions (EQ-5D) in this patient group was found, but less support was found for the 36-Item Short-Form Health Survey (SF-36), which some patients indicated did not cover areas of relevance to them. The Parkinson's Disease Questionnaire (PDQ-39) has been assessed for its suitability in this patient group, but it was found to lack some aspects of quality of life that are important to patients with PSP.

AB - Introduction Progressive supranuclear palsy (PSP) is a neurodegenerative disorder causing parkinsonism, visual dysfunction, and balance impairment, as well as cognitive impairment and psychiatric complications. These problems, together with the emotional and social consequences of having a progressively disabling disease with shortened life expectancy, have an enormous impact on patients' health-related quality of life (HRQoL). PSP was first delineated as a distinct disorder, separate from Parkinson's disease, in 1962. It is sometimes referred to as Steele–Richardson–Olszewski syndrome after the scientists who originally described the condition. It is estimated that the disease has a prevalence of 6 per 100,000, similar to that of motor neuron disease, with the average age of onset being in the seventh decade. Mean survival from the onset of symptoms is approximately 6 years. To date, there has been little validation of any HR-QoL generic instruments in this patient group. In one small-scale study, some limited evidence for the appropriateness of the European Quality of Life Five Dimensions (EQ-5D) in this patient group was found, but less support was found for the 36-Item Short-Form Health Survey (SF-36), which some patients indicated did not cover areas of relevance to them. The Parkinson's Disease Questionnaire (PDQ-39) has been assessed for its suitability in this patient group, but it was found to lack some aspects of quality of life that are important to patients with PSP.

UR - http://www.scopus.com/inward/record.url?scp=84926079424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84926079424&partnerID=8YFLogxK

U2 - 10.1017/CBO9780511975363.006

DO - 10.1017/CBO9780511975363.006

M3 - Chapter

AN - SCOPUS:84926079424

SN - 9780521829014

SP - 52

EP - 59

BT - Quality of Life Measurement in Neurodegenerative and Related Conditions

PB - Cambridge University Press

ER -